
Episode: 83 - Patrick Baeuerle and Jeffrey Miller on T Cell and Immune Cell Engagement
Notas del episodio
T cell and immune cell engagement is gaining traction, but what makes it different from other therapies? Patrick Baeuerle, Ph.D., chief scientific advisor at Cullinan Therapeutics, and Jeffrey Miller, M.D., deputy director of Masonic Cancer Center, join The Chain to discuss the advantages, similarities, and differences of T cell and immune cell engagers, and how they compare to other modalities such as CAR T cells. Hosted by Laszlo Radvanyi, Ph.D., their conversation covers engineering recognition of multiple targets, prospects for peptide MHC engagers and NK cells engagers, and the application of these modalities to oncology and beyond.
Links from this episode:
University of Toronto, Department of Immunology
University of Toronto
Cullinan Therapeutics
Masonic Cancer Center
The Chain explores the lives, careers, research, and discoveries of protein engineers and scientists, the impact their work is having on the field, and where the industry is headed. Tune in to stay up to date on the newest advancements and to hear the stories that are impacting the world of biologics.
Capítulos
Cargando capítulos…
Todos los episodios de The Chain: Protein Engineering Podcast